Exenatide
Approved · EMAAlso known as Bydureon, Byetta, Exendin 4, Exendin-4+3 more
Bydureon, Byetta, Exendin 4, Exendin-4, Exenatida, Exenatide synthetic, Synthetic exendin-4.
Recent clinical, regulatory, research and industry developments relating to this drug.
Pilot Study of Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes
Brain Systems and Behaviors Underlying Response to Obesity Treatment in Children
Effects of GLP-1 Analogues and Agonists on the Gut Microbiota: A Systematic Review.
Otolaryngologic Side Effects of GLP-1 Receptor Agonists.
Drug Safety Update: Exenatide (Byetta ▼): risk of severe pancreatitis and renal failure
Evidence confidence
How strongly the incorporated evidence supports specific clinical claims about this treatment. A confidence figure is a current summary of evidence strength, not a permanent verdict.
— 23 supporting evidence families · 5 well-powered no-effect results
Confidence is moderated by well-powered no-effect evidence and limited publication incorporation, despite broad trial support.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Bydureon is indicated in adults 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products when… Show full indicationShow less
Bydureon is indicated in adults 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products when the therapy in use, together with diet and exercise, does not provide adequate glycaemic control (see section 4.4, 4.5 and 5.1 for available data on different combinations). Bydureon is indicated for treatment of type 2 diabetes mellitus in combination with: Metformin Sulphonylurea Thiazolidinedione Metformin and sulphonylurea Metformin and thiazolidinedione in adults who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies.
Indication: Byetta is indicated for treatment of type-2 diabetes mellitus in combination with: metformin; sulphonylureas; thiazolidinediones; metformin and a sulphonylurea; metformin and a… Show full indicationShow less
Byetta is indicated for treatment of type-2 diabetes mellitus in combination with: metformin; sulphonylureas; thiazolidinediones; metformin and a sulphonylurea; metformin and a thiazolidinedione; in adults who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies. Byetta is also indicated as adjunctive therapy to basal insulin with or without metformin and / or pioglitazone in adults who have not achieved adequate glycaemic control with these agents.
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Contains public sector information from the Medicines and Healthcare products Regulatory Agency (MHRA) licensed under the Open Government Licence (OGL v3).
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Pilot Study of Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- Diabetes4
- Diabetes care2
- Diabetes, obesity & metabolism2
- Hepatology (Baltimore, Md.)2
- Journal of diabetes investigation2
- Acta neuropathologica communications1
- Trautmann M3
- Cersosimo E2
- Ciociaro D2
- Daniele G2
- DeFronzo R2
- Drucker DJ2
- Fox P2
- Gastaldelli A2
- Graduate School of Medicine2
- Institute of Clinical Physiology2
- Lilly Research Laboratories Japan2
- National Institute on Aging2
- Beth Israel Deaconess Medical Center1
- Brain and Cognition Discovery Foundation1
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Acts on the same molecular target as Exenatide, with 11 overlapping disease areas.
Acts on the same molecular target as Exenatide, with 12 overlapping disease areas.
Acts on the same molecular target as Exenatide, with 8 overlapping disease areas.
Studied across 14 of the same disease areas as Exenatide in the shared literature.
Acts on the same molecular target as Exenatide, with an overlapping disease area.
Studied across 9 of the same disease areas as Exenatide in the shared literature.
Studied across 8 of the same disease areas as Exenatide in the shared literature.
Studied across 6 of the same disease areas as Exenatide in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.